ReviewUrologie (Heidelberg, Germany)2023
[Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer].
Review in Urologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrom 1941 to 2014, metastatic hormone-sensitive prostate cancer (mHSPC) was solely treated by surgery or medical castration (androgen deprivation therapy [ADT]). In 2014, the addition of docetaxel chemotherapy (CTX) was shown to significantly improve overall survival. However, CTX is not ideal for all patients. Some are too old, too sick, or oppose to treatment with CTX. Therefore, alternatives with low toxicity and equal efficacy were explored. Abiraterone (Abi), apalutamide (Apa), and enzalutamide (Enza) are new antihormonal therapies (NHT) which meet these requirements.
objectivesTo review the role of NHTs + ADT in mHSPC. MATERIALS AND
methodsPrerequisites and challenges are summarized and key data on combination therapy with NHTs + ADT in mHSPC are reviewed.
resultsTreatment of mHSPC with Abi, Apa, or Enza represents a big step forward. Especially for patients who do not qualify for CTX or oppose CTX, NHTs are a valid alternative. The use of Abi is more challenging than the use of Apa and Enza due to more complex conditions that need to be fulfilled for its use. Thus, the time for the patient in the mHSPC stage will be longer with more intensive androgen deprivation, which may lead to increased risk of cardiovascular disease and osteoporosis. When choosing a treatment with NHTs in this setting, possible follow-up treatment needs to be considered.
conclusionsTreatment of mHSPC using NHTs + ADT is an important new standard. Almost every patient can be treated with one of the NHTs with relatively low risk of toxicity. Therefore, these treatments are widely used. In the future, the addition of new therapeutics could further strengthen the relevance of NHTs in the mHSPC setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.